

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A composition comprising at least one component selected from the group consisting of:

- (a) delipidated and deglycolipidated *M. vaccae* cells that have been treated by alkaline hydrolysis;
- (b) delipidated and deglycolipidated *M. vaccae* cells that have been treated by acid hydrolysis;
- (c) delipidated and deglycolipidated *M. vaccae* cells that have been treated with periodic acid;
- (d) delipidated and deglycolipidated *M. vaccae* cells that have been treated by alkaline hydrolysis and by acid hydrolysis;
- (e) delipidated and deglycolipidated *M. vaccae* cells that have been treated by alkaline hydrolysis and treated with periodic acid;
- (f) delipidated and deglycolipidated *M. vaccae* cells that have been treated with Proteinase K; and
- (g) delipidated and deglycolipidated *M. vaccae* cells that have been treated by hydrofluoric acid hydrolysis.

Claim 2 (new): A composition comprising a component prepared by:

- (a) inactivating *Mycobacterium vaccae* cells;
- (b) freeze-drying the inactivated cells to provide a freeze dried material;
- (c) contacting the freeze dried material with a chloroform-methanol mixture in an amount sufficient to extract lipids to provide a delipidated material;
- (d) refluxing the delipidated material with an ethanol-water mixture in an amount sufficient to remove glycolipids to provide a delipidated and deglycolipidated material; and

(e) contacting the delipidated and deglycolipidated material with sulfuric acid in an amount sufficient to cleave acid-labile linkages to provide the component.

Claim 3 (new): The composition of claim 2, wherein the component contains galactose in an amount less than 9.7% of total carbohydrate.

Claim 4 (new): The composition of claim 2, wherein the component contains glucosamine in an amount greater than 3.7% of total carbohydrate.

Claim 5 (new): The composition of claim 2, wherein the component is depleted of arabinogalactan compared to untreated delipidated and deglycolipidated *M. vaccae* cells.

Claim 6 (new): The composition of claim 2, wherein the component contains galactosamine in an amount less than 26.6% of total carbohydrate.

Claim 7 (new): The composition of claim 2, wherein the component contains glucose in an amount greater than 56.9% of total carbohydrate.

Claim 8 (new): The composition of claim 2, wherein the component contains mannose in an amount greater than 3.2% of total carbohydrate.

Claim 9 (new): The composition of any one of claims 1 and 2, wherein the composition is effective at modulating the amount of an interleukin molecule involved in an antigen-specific Th2-mediated immune response in a patient.

Claim 10 (new): A method for the treatment of a disorder in a patient, comprising administering to the patient a composition according to any one of claims 1 and 2, the disorder being selected from the group consisting of: disorders of the respiratory system and allergic disorders.

Claim 11 (new): The method of claim 10, wherein the disorder is selected from the group consisting of: mycobacterial infections, asthma, sarcoidosis, allergic rhinitis, and atopic dermatitis and lung cancers.

Claim 12 (new): A method for the reduction of eosinophilia in a patient, comprising administering to the patient a composition according to any one of claims 1 and 2.

Claim 13 (new): A method for enhancing IL-10 production, comprising administering a composition according to any one of claims 1 and 2

Claim 14 (new): A method for the treatment of a disorder in a patient, comprising administering to the patient a composition according to any one of claims 1 and 2, wherein the disorder is selected from the group consisting of: atherosclerosis; cancer; hypercholesterolemia; bacterial infections; and insulin-dependent diabetes mellitus.

Claim 15 (new): A method for activating $\gamma\delta$ T cells, $\gamma\delta$ T cells or NK cells in a patient, comprising administering a composition of any one of claims 1 and 2.

Claim 16 (new): A method for repairing epithelium in a patient, comprising administering a composition of any one of claims 1 and 2.

Claim 17 (new): A method for modulating a disorder characterized by an antigen specific Th2-mediated immune response in a patient, comprising administering a composition of any one of claims 1 and 2 to the patient.

Claim 18 (new): The method of claim 17, wherein the disorder is selected from the group consisting of:

- (a) an hypersensitivity immune reaction;
- (b) a pathogenic immune response caused by excessive Th2 activation; and
- (c) a disorder caused by the suppression of a IFN-gamma-mediated immune function.

Claim 19 (new): The method of claim 18, wherein the hypersensitivity reaction is associated with a disorder selected from the group consisting of: atopic dermatitis; asthma; and allergic rhinitis.

Claim 20 (new): A method for preventing or reducing the severity of an immune response to a specific antigen in a patient, comprising administering to the patient the specific antigen and a composition of any one of claims 1 and 2.

Claim 21 (new): A composition comprising at least one component selected from the group consisting of:

- (a) delipidated and deglycolipidated mycobacterial cells that have been treated by alkaline hydrolysis;
- (b) delipidated and deglycolipidated mycobacterial cells that have been treated by acid hydrolysis;
- (c) delipidated and deglycolipidated mycobacterial cells that have been treated with periodic acid;
- (d) delipidated and deglycolipidated mycobacterial cells that have been treated by alkaline hydrolysis and by acid hydrolysis;
- (e) delipidated and deglycolipidated mycobacterial cells that have been treated by alkaline hydrolysis and treated with periodic acid;
- (f) delipidated and deglycolipidated mycobacterial cells that have been treated with Proteinase K; and
- (g) delipidated and deglycolipidated mycobacterial cells that have been treated by hydrofluoric acid hydrolysis.

Claim 22 (new): The composition of claim 21, wherein the mycobacterial cells are selected from the group consisting of: *Mycobacterium tuberculosis* and *Mycobacterium smegmatis*.